Printer Friendly

Once-a-Week Home Test Lowers HbA1c, Improving Diabetes Control; Study Presented at American Diabetes Association Annual Meeting.

SAN ANTONIO, June 12 /PRNewswire/ --

A home testing system that combines a rapid blood glucose (sugar) test with a new once-a-week test for glycated protein (fructosamine) is able to help patients with diabetes lower their HbA1c score and improve the control of their disease, according to a poster session hosted today at the 60th Scientific Sessions of the American Diabetes Association.

Steven V. Edelman, M.D., primary investigator of the study, associate professor of medicine at the University of California, San Diego and executive director, conference founder of Taking Control of Your Diabetes(TM), reported that patients who measured their glucose levels from one to four times a day and their fructosamine levels once a week were able to significantly improve their glycemic control and lower their HbA1c score, compared to patients who tested only their glucose.

Previously released research shows that over 55 percent of Type 2 patients are in poor control, putting them at risk of such serious complications as blindness and kidney failure. Earlier studies have suggested in Type 2 patients that self-monitoring of blood glucose alone may not effectively allow them to obtain a measurement of overall glucose control, thereby limiting their ability to reduce their HbA1c levels. (Faas, et.al, Diabetes Care 20:1482-1486, 1997, Oki et. al. The Diabetes Educator 23: 419-424, 1997 and Bouma, et. al, Diabetes Care 22:904-907, 1999).

The weekly fructosamine test, introduced by LXN Corporation as the GlucoProtein(R) test, indicates the average of continuous glucose changes over the prior two- to three-week time period. In contrast, traditional glucose tests provide only a snapshot of glycemic control at any one given moment in time. The GlucoProtein test complements the existing laboratory assay for HbA1c, another type of glycated protein test, which is performed every two to three months and is considered an important tool for measuring and managing overall glucose control. Patients are able to perform both glucose and GlucoProtein testing on the same meter, available from LXN Corporation as the IN CHARGE(TM) Diabetes Control System.

At the end of the three-month study, patients who utilized both glucose and GlucoProtein testing showed a 13 percent improvement in their HbA1c test results (from 9.2 percent to 8.0 percent, p<0.0001), versus a three percent improvement for patients who conducted glucose-only testing (from 9.4 percent to 9.1 percent, p=not significant).

"These results indicate that fructosamine (GlucoProtein) testing is a valuable new tool for helping patients with diabetes obtain better and more timely information on their overall glucose control," said Dr. Edelman. "This information empowers them to be self-advocates, making them more effective in working with their healthcare professional to manage their disease."

In the study, patients performing weekly GlucoProtein tests along with daily glucose tests were able to discover potential problems, allowing their study investigators to recommend changes in medication, diet or exercise to improve the management of their disease. Since patients who conducted glucose-only testing were not able to obtain average levels or intermediate-term trends, their ability to assess overall glucose control and correct problems was limited.

Approximately four percent of the world's population, or 155 million individuals, have diabetes, a number that is expected to increase to 240 million by the year 2010. Currently there are more than 17 million people with diabetes in the U.S. alone. Approximately 90 percent of these suffer from Type 2 diabetes, a condition that occurs when the body fails to make enough of, or to properly interact with the hormone insulin, which is required to convert food into energy.

Based in San Diego, Calif., LXN Corporation is a privately held company formed in January 1994. It is a leader in the development and marketing of innovative products and services for diabetes management. The company is committed to helping people with diabetes live longer, healthier lives through improved glucose control. LXN markets the IN CHARGE(TM) Diabetes Control System for patient self-testing and the Duet(R) Diabetes Control System, developed for in-office testing of a patients overall glucose control. Further information is available at LXN's website www.inchargenow.com
COPYRIGHT 2000 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 12, 2000
Words:683
Previous Article:Inforte CEO Honored by Ernst & Young as Entrepreneur of the Year.
Next Article:Lycos Network and FreeLotto Join Forces.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters